Compare Dyne Therapeutics Inc. Common Stock (DYN) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs PepsiCo, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while PepsiCo, Inc. trades at $129.93 (market cap $173.48B). The key difference: PepsiCo, Inc. is far larger — about 60.7× Dyne Therapeutics Inc. Common Stock's market cap, and PepsiCo, Inc. pays a 4.65% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and PepsiCo, Inc. for 108 Days on average.
| DYN | PEP | |
|---|---|---|
Market Cap | $2.86B | $173.48B |
Volume | 3,341,579 | 11,774,872 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $170.44 |
52-Week Low | $14.60 | $123.64 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $2.18B | $214.19B |
Dividend Yield | — | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PepsiCo (PEP) trades at $129.27, up 2.01% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $93.93B revenue and 11.09% net margin. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a cautious outlook with 67.4% hold ratings.
PEP offers stable dividend income and consistent profitability, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $142.38 suggests 10% upside potential, but technical weakness and mixed sentiment warrant careful monitoring of North American performance in upcoming earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
